JP2018505183A - エボラウイルス疾患の処置のための方法及び医薬組成物 - Google Patents

エボラウイルス疾患の処置のための方法及び医薬組成物 Download PDF

Info

Publication number
JP2018505183A
JP2018505183A JP2017540652A JP2017540652A JP2018505183A JP 2018505183 A JP2018505183 A JP 2018505183A JP 2017540652 A JP2017540652 A JP 2017540652A JP 2017540652 A JP2017540652 A JP 2017540652A JP 2018505183 A JP2018505183 A JP 2018505183A
Authority
JP
Japan
Prior art keywords
ebola virus
subject
favipiravir
treatment
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017540652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505183A5 (enExample
Inventor
アングラレ，グザヴィエ
マルヴィ，ドゥニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chu De Bordeaux
Original Assignee
Chu De Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chu De Bordeaux filed Critical Chu De Bordeaux
Publication of JP2018505183A publication Critical patent/JP2018505183A/ja
Publication of JP2018505183A5 publication Critical patent/JP2018505183A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017540652A 2015-01-28 2016-01-27 エボラウイルス疾患の処置のための方法及び医薬組成物 Pending JP2018505183A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IB2015000334 2015-01-28
IBPCT/IB2015/000334 2015-01-28
IB2015000351 2015-02-19
IBPCT/IB2015/000351 2015-02-19
PCT/EP2016/051645 WO2016120301A1 (en) 2015-01-28 2016-01-27 Methods and pharmaceutical compositions for the treatment of ebola virus disease

Publications (2)

Publication Number Publication Date
JP2018505183A true JP2018505183A (ja) 2018-02-22
JP2018505183A5 JP2018505183A5 (enExample) 2018-12-20

Family

ID=55272459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540652A Pending JP2018505183A (ja) 2015-01-28 2016-01-27 エボラウイルス疾患の処置のための方法及び医薬組成物

Country Status (4)

Country Link
US (1) US10098879B2 (enExample)
EP (1) EP3250206A1 (enExample)
JP (1) JP2018505183A (enExample)
WO (1) WO2016120301A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158020A1 (en) * 2020-05-23 2023-05-25 Alexandre Vasilievich Ivaschenko Method for treating RNA viral infections, including COVID-19 (SARS-CoV-2)
WO2022131112A1 (ja) * 2020-12-18 2022-06-23 富士フイルム富山化学株式会社 医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01001843A (es) 1998-08-20 2002-04-08 Toyama Chemical Co Ltd Derivados de carboxamida heterociclica con nitrogeno o sales derivados de los mismos y agentes antivirales que comprenden los mismos.
MX2011009440A (es) 2009-03-13 2011-11-04 Toyama Chemical Co Ltd Tableta y polvo granulado que contiene 6-fluoro-3-hidroxi-2-pirazi ncarboxamida.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTIVIRAL RESEARCH, vol. 104, JPN6019027451, 2014, pages 153 - 155, ISSN: 0004224723 *
FOLIA MEDICA CRACOVIENSIA, vol. 3, JPN6019027453, 2014, pages 67 - 77, ISSN: 0004224724 *

Also Published As

Publication number Publication date
US10098879B2 (en) 2018-10-16
EP3250206A1 (en) 2017-12-06
US20180021333A1 (en) 2018-01-25
WO2016120301A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
Happi et al. Lassa fever diagnostics: past, present, and future
US12018334B2 (en) Controls for nucleic acid assays
US9556487B2 (en) Methods of using miRNA from bodily fluids for early detection and monitoring of mild cognitive impairment (MCI) and alzheimer's disease (AD)
WO2015048098A1 (en) Diagnostic methods for infectious disease using endogenous gene expression
US12215386B2 (en) Blood biomarkers for appendicitis and diagnostics methods using biomarkers
Lin et al. The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection
CN112608995B (zh) 一种肺结核病特异性标志物及应用和试剂盒
Bayomy et al. Mir-142-5p as an indicator of autoimmune processes in childhood idiopathic nephrotic syndrome and as a part of MicroRNAs expression panels for its diagnosis and prediction of response to steroid treatment
US10098879B2 (en) Methods and pharmaceutical compositions for the treatment of ebola virus disease
EP2985351B1 (en) A circulating non-coding rna as predictor of mortality in patients with acute kidney injury
KR102403807B1 (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
US20130029334A1 (en) mRNA As Biomarkers For Liver Injury or Other Liver Perturbations
Othumpangat et al. Differential Expression of Serum Exosome microRNAs and Cytokines in Influenza A and B Patients Collected in the 2016 and 2017 Influenza Seasons. Pathogens. 2021; 10 (2)
CN115927582A (zh) 一种基于检测itm2a基因表达水平的脓毒症诊断试剂盒
WO2022271201A2 (en) Ace2 and tmprss2 gene expression as predictive markers of covid-19 severity
Snigdha et al. Bioinformatics approach to analyse COVID-19 biomarkers accountable for generation of intracranial aneurysm in COVID-19 patients
Rickett Determinants of patient survival following acute Ebola virus infection
Ratnasiri Defining Human Immune Responses to Viruses by Embracing Heterogeneity
Ahmed Ibrahim et al. Evaluation of the expression of lncRNA PAX8-AS1 and mRNA LAIR-2 in chronic hepatitis C virus (CHC) among Egyptian patients
WO2025137577A1 (en) Short viral rnas (svrnas) with theragnostic potential in infection with sars-cov-2 and related viruses
CA3220934A1 (en) Biomarkers and methods for classifying subjects following viral exposure
US20170218466A1 (en) Detection of circulating jc polyomavirus (jcpyv) micrornas as biomarker for jcpyv infection
JP2011137659A (ja) 遺伝子発現レベルを指標とした化学物質の生体に対する影響の検出・予測方法
Pan et al. A case of human infection with avian Influenza A/H7N9 virus in Beijing: virological and serological analysis
CN116622866A (zh) 布鲁氏菌病的外泌体miRNA标志物及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190207

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303